Focused On-demand Library for Dual specificity protein phosphatase CDC14C

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
A4D256

UPID:
CC14C_HUMAN

ALTERNATIVE NAMES:
CDC14 cell division cycle 14 homolog C

ALTERNATIVE UPACC:
A4D256; Q2VIP7; Q6NUS3; Q8NCT2

BACKGROUND:
The enzyme Dual specificity protein phosphatase CDC14C, alternatively named CDC14 cell division cycle 14 homolog C, is distinguished by its preference for dephosphorylating proteins influenced by proline-directed kinases. This specificity highlights its integral role in controlling key cellular mechanisms, including cell cycle progression and signaling.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Dual specificity protein phosphatase CDC14C holds the key to unlocking novel therapeutic approaches. Given its central role in managing cell cycle and signaling, targeting this phosphatase could lead to breakthrough treatments for conditions associated with these critical pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.